What are the types of column in HPLC?
HPLC columns are grouped by the separation mechanism they use, and in pharmacopoeial work each packing is additionally identified by a USP “L” designation. The eight working categories are:
- Reversed phase — hydrophobic partitioning (C18, C8, phenyl, PFP)
- Normal phase — adsorption onto a polar surface (bare silica, amino, diol, cyano)
- HILIC — hydrophilic partitioning for very polar analytes
- Ion-exchange — electrostatic retention of charged species
- Size-exclusion — hydrodynamic size in solution
- Chiral — stereoselective recognition of enantiomers
- Affinity — specific biochemical binding
- Mixed-mode — two mechanisms on one particle
Those eight are the modes. Separately, the physical format — fully porous, superficially porous (core–shell), hybrid or monolithic — sets efficiency and back pressure. A column is fully specified only when you state both, plus particle size, pore size, dimensions and the L-code.
Most articles on this topic stop at the eight modes. In a regulated laboratory that is not enough: a monograph names a packing by L-designation, an inspector asks whether your substitution was permitted, and two columns carrying the same L-code can give visibly different chromatograms. This guide covers the modes, the USP L-code system, what USP 〈621〉 actually lets you change, and the traps that cost columns and out-of-specification investigations.
How HPLC columns are classified
Column classification only becomes useful when you separate three independent axes. Mixing them is why “what type of column is this?” so often gets a confused answer.
Axis 1 — Separation mechanism
Partitioning, adsorption, ion-exchange, size exclusion, affinity, stereoselective recognition, or a deliberate combination. This decides whether your analytes separate at all.
Axis 2 — Particle architecture
Fully porous, superficially porous (core–shell), organic–inorganic hybrid, or a monolithic rod. This decides efficiency per unit length and the back pressure your pump must deliver.
Axis 3 — Pharmacopoeial identity
The USP L-designation. This is the axis that governs compliance: monographs specify packings as L1, L7, L43 and so on, not by brand.[3]
A working description therefore reads: “150 × 4.6 mm, 3.5 µm fully porous C18, USP L1, 100 Å pore” — mechanism, architecture and pharmacopoeial identity in one line. If you inherited a method that names only a brand, reconstruct this line before you attempt any transfer. See our companion guide to the working principle and instrumentation of HPLC for how the column sits inside the wider system.
The USP L-code list: how HPLC columns are classified as per USP
The L-nomenclature was introduced in the Fourth Supplement to USP XIX in 1978 and has grown continuously since. USP maintains a Chromatographic Columns Database listing the columns actually used to validate the procedures published in USP–NF; a designation is assigned a number only when the text referring to it becomes official.[3] Published listings now run past L120.[2]
USP L-designation lookup
Type a code, a chemistry or an application — for example C18, cation, amino, L43. The packing descriptions reproduce the wording used in USP–NF reagent listings.[2]
Showing all 16 designations
| L-code | USP packing description | Common name | Typical use |
|---|---|---|---|
L1 | Octadecyl silane chemically bonded to porous or non-porous silica or ceramic micro-particles or superficially porous particles, 1.5 to 10 µm in diameter, or a monolithic rod. | C18 / ODS | The default reversed-phase packing for most assay and related-substance monographs |
L3 | Porous silica particles or superficially porous particles, 1.5 to 10 µm in diameter, or a monolithic silica rod. | Bare silica | Normal phase, and HILIC separations of very polar analytes |
L7 | Octylsilane chemically bonded to totally or superficially porous silica particles, 1.5 to 10 µm in diameter, or a monolithic silica rod. | C8 | Reversed phase where C18 over-retains; shorter run times |
L8 | Essentially monomolecular layer of aminopropylsilane chemically bonded to totally porous silica gel support, 1.5 to 10 µm in diameter, or a monolithic silica rod. | Amino / NH2 | Sugars, carbohydrates, weak anion exchange, HILIC |
L10 | Nitrile groups chemically bonded to porous silica particles or superficially porous particles, 1.5 to 10 µm in diameter, or a monolithic silica rod. | Cyano / CN | Dual-mode packing usable in normal or reversed phase |
L11 | Phenyl groups chemically bonded to porous silica particles or superficially porous particles, 1.5 to 10 µm in diameter, or a monolithic silica rod. | Phenyl | Aromatic and positional isomers via pi–pi selectivity |
L13 | Trimethylsilane chemically bonded to porous silica particles, 3 to 10 µm in diameter. | C1 / TMS | Very weakly retentive reversed phase for hydrophobic analytes |
L14 | Silica gel having a chemically bonded strongly basic quaternary ammonium anion-exchange coating, 5 to 10 µm in diameter. | Strong anion exchange | Acidic and anionic analytes, organic acids |
L17 | Strong cation-exchange resin consisting of sulfonated cross-linked styrene-divinylbenzene copolymer in the hydrogen form, 6 to 12 µm in diameter. | SCX, hydrogen form | Organic acids, sugars, ion-exclusion separations |
L19 | Strong cation-exchange resin consisting of sulfonated cross-linked styrene-divinylbenzene copolymer in the calcium form, 5 to 15 µm in diameter. | SCX, calcium form | Carbohydrate and polyol separations |
L20 | Dihydroxypropane groups chemically bonded to porous silica or hybrid particles, 1.5 to 10 µm in diameter, or a monolithic silica rod. | Diol | Normal phase, HILIC, aqueous size exclusion of proteins |
L21 | Rigid, spherical styrene-divinylbenzene copolymer, 3 to 30 µm in diameter. | Polymeric SEC | Size-exclusion and gel-permeation work; wide pH tolerance |
L26 | Butyl silane chemically bonded to totally porous or superficially porous silica particles, 1.5 to 10 µm in diameter. | C4 | Proteins and peptides, where C18 binds too strongly |
L34 | Strong cation-exchange resin consisting of sulfonated cross-linked styrene-divinylbenzene copolymer in the lead form, 7 to 9 µm in diameter. | SCX, lead form | Sugar alcohols and specific carbohydrate monographs |
L43 | Pentafluorophenyl groups chemically bonded to silica particles or superficially porous particles by a propyl spacer, 1.5 to 10 µm in diameter. | PFP / PFPP | Halogenated, positional-isomer and basic analytes; orthogonal to C18 |
L60 | Spherical, porous silica gel or superficially porous particles, 10 µm or less in diameter, the surface of which has been covalently modified with alkyl amide groups and endcapped. | Polar-embedded amide | Basic drugs and highly aqueous mobile phases; resists dewetting |
Scroll the table sideways on a phone. 16 of the most frequently specified designations shown.
The L-code is a category, not a specification. More than 800 distinct commercial columns carry the L1 designation, built on different base silicas, with different bonding reagents and different synthetic routes. Four C18 phases run under identical conditions can produce visibly different chromatograms.[4] An L-code match is a starting point for column equivalence, never proof of it. Where a like-for-like replacement matters, use a column-characterisation approach such as the hydrophobic subtraction model rather than the L-number alone, and confirm equivalence with a system suitability run.
Choosing an HPLC column: a working selector
Column selection aid
Answer three questions about the analyte. The tool returns the separation mode, a typical starting phase and the matching USP designation. It is a starting point for method development, not a substitute for scouting runs.
1. Polarity and aqueous solubility
2. Charge state at working pH
3. Size and stereochemistry
Choose one option in each of the three groups
The recommended separation mode, starting stationary phase and USP designation will appear here.
Column types in detail
1. Reversed-phase columns
Retention comes from hydrophobic interaction between nonpolar analytes and an alkyl-bonded surface, eluted with an aqueous mobile phase modified with acetonitrile or methanol. It is the default mode for small-molecule pharmaceutical assay and impurity work because it is robust, reproducible and compatible with mass spectrometry.
L1 C18 · L7 C8 · L26 C4 · L11 phenyl · L43 PFP · L60 polar-embedded amide.
Two practical limits govern the mode. First, conventional C18-silica columns are typically recommended only up to about pH 8, above which the silica support begins to dissolve and the bonded phase hydrolyses, costing efficiency and retention.[6] Organic–inorganic hybrid particles were developed specifically to widen that window; check the manufacturer’s certificate for the range claimed for your part number rather than assuming a general figure. Second, highly aqueous mobile phases can cause retention loss — discussed below.
2. Normal-phase columns
Adsorption of polar analytes onto a polar surface, eluted with a nonpolar mobile phase such as hexane or heptane with an alcohol modifier. Bare silica L3, amino L8, diol L20 and cyano L10 are the usual packings. The mode retains real value for positional and geometric isomers and for lipid work, but retention drifts with trace water in the solvent, and the mobile phases are poorly suited to mass spectrometry and to routine QC in a humid climate.
3. HILIC columns
Hydrophilic interaction chromatography retains very polar analytes that reversed phase cannot hold, using a polar stationary phase with a high-organic mobile phase and a water-rich layer at the surface. Bare silica L3, amide L60 and zwitterionic phases are the common choices. HILIC is MS-friendly, which is its main advantage over ion-exchange for polar metabolites, but it is sensitive to the water content of the mobile phase and needs longer re-equilibration than reversed phase.
4. Ion-exchange columns
Charged analytes are retained electrostatically by fixed charges on the packing. Strong anion exchange L14 holds acids and anions; strong cation exchange in hydrogen L17, calcium L19 or lead L34 form appears in specific carbohydrate and organic-acid monographs. Polymeric supports tolerate a far wider pH range than silica. The cost is salt in the eluent, which limits direct MS coupling.
5. Size-exclusion columns
Separation by hydrodynamic size, with larger molecules excluded from the pores and eluting first. Rigid styrene-divinylbenzene L21 and diol-bonded silica L20 are typical. This is the standard technique for aggregate and high-molecular-weight species testing on therapeutic proteins. Resolution is inherently limited, and any secondary interaction with the packing invalidates the size calibration — which is why ionic strength control matters more here than in any other mode.
6. Chiral columns
Enantiomers are resolved through stereoselective interaction with a chiral selector: polysaccharide derivatives (amylose and cellulose carbamates) dominate, with cyclodextrin, protein-based, ligand-exchange and Pirkle-type brush phases used for specific problems. Where a monograph specifies a chiral packing it carries its own L-designation; confirm the exact code in the current monograph rather than assuming it, because chiral designations are assigned individually and are easy to mis-transcribe. Immobilised polysaccharide phases tolerate a much wider solvent range than coated ones, which matters when the sample only dissolves in a solvent that would strip a coated phase.
7. Affinity and specialty columns
Retention by specific biochemical recognition — Protein A or G for antibody capture and titre, immobilised metal affinity for histidine-tagged proteins, immunoaffinity for targeted extraction, and molecularly imprinted polymers for selective clean-up. Selectivity is unmatched, cost per column is high, and applicability is narrow by design.
8. Mixed-mode columns
Two retention mechanisms on one particle, most often reversed phase plus ion exchange. Adjusting ionic strength and organic content tunes which mechanism dominates, giving selectivity that neither mode reaches alone. Useful for impurity profiles containing both neutral and permanently charged species. Method development is correspondingly harder, and robustness testing under ICH Q2(R2) deserves extra attention because two mechanisms respond to a single parameter change.[7]
Comparison of all HPLC column types
| Mode | Mechanism | Typical phase | USP code | Best for | Main limitation |
|---|---|---|---|---|---|
| Reversed phase | Hydrophobic partitioning | C18, C8, phenyl, PFP | L1 L7 L11 L43 | APIs, related substances, dissolution | Weak retention of very polar analytes |
| Normal phase | Polar adsorption | Silica, amino, diol, cyano | L3 L8 L20 L10 | Isomers, lipids, fat-soluble vitamins | Moisture sensitive; not MS friendly |
| HILIC | Hydrophilic partitioning | Silica, amide, zwitterionic | L3 L60 | Polar drugs, metabolites, sugars | Long re-equilibration; water sensitive |
| Anion exchange | Electrostatic | Quaternary ammonium | L14 | Organic acids, anionic APIs | Salt gradients complicate MS |
| Cation exchange | Electrostatic | Sulfonated SDVB | L17 L19 L34 | Basic analytes, sugars, ion exclusion | Requires tight pH control |
| Size exclusion | Hydrodynamic size | SDVB, diol silica | L21 L20 | Protein aggregates, polymer MW | Low resolving power |
| Chiral | Stereoselective recognition | Polysaccharide, cyclodextrin | Monograph specific | Enantiomeric purity | High cost; slow method development |
| Affinity | Biochemical binding | Protein A/G, IMAC | Not generally L-coded | Antibody titre, tagged proteins | Very narrow applicability |
| Mixed mode | Two mechanisms | RP plus IEX ligands | Varies | Mixed neutral and ionic impurities | Complex, harder to validate |
Scroll sideways to see all six columns.
Particle architecture: what actually sets efficiency
Two columns with the same L-code and the same dimensions can differ by a factor of three in plate count, because efficiency is set by particle architecture rather than by bonded chemistry.
Superficially porous (core–shell) particles are the clearest example. Sub-3 µm superficially porous columns rival the efficiency of columns packed with sub-2 µm fully porous particles while generating only about half the back pressure — typically operating at one-half to one-third of the pressure of a fully porous sub-2 µm column.[5] That is what makes them attractive on a conventional 400 bar HPLC: most of the UHPLC efficiency benefit without replacing the instrument. Materials at 1.3 µm have reached minimum plate heights of about 2 µm, corresponding to up to 500,000 plates per metre, but sub-2 µm superficially porous particles only show their benefit beyond roughly 800 bar and need instruments rated to 1000–1300 bar.[5]
Pressure itself changes retention. Across 500 bar increments, retention factors for neutral low-molecular-weight compounds shift by roughly 2–12%, while higher-molecular-weight neutrals and ionised acids and bases can shift by up to 50%.[4] When you transfer a method from 5 µm to sub-2 µm particles you are changing operating pressure substantially, so selectivity shifts are a foreseeable outcome, not an anomaly. Plan the transfer with a system suitability check, and document it.
If you are budgeting an analytical laboratory rather than choosing a column, the instrument decision sits alongside this one — our comparison of current HPLC instrument models, Indian pricing and service coverage covers the hardware side, and QC instrumentation is a recognised line item in the pharmaceutical plant setup cost calculator.
What USP 621 lets you change — and what it does not
This is the question that decides whether a column swap is an adjustment or a change requiring revalidation. USP General Chapter 621 Chromatography, in the harmonised text official from 1 December 2022, sets out permitted adjustments to a prescribed procedure. Adjustments within these limits are allowed provided system suitability is still met; anything beyond them is a modification.[1]
Allowable adjustments under USP 621
Use the tabs to switch between isocratic and gradient liquid chromatography. Verify against the current official text before acting on any of these values.
| Parameter | Permitted adjustment |
|---|---|
| Column length to particle size ratio (L/dp) | Held constant, or within −25% to +50% of the prescribed ratio |
| Particle size | May be changed provided the L/dp ratio stays within the band above |
| Column internal diameter | Adjustable without changing particle size or column length |
| Flow rate | ±50% where column dimensions are unchanged; a further ±50% is permitted after a column adjustment |
| Mobile phase pH | ±0.2 pH units |
| Buffer concentration | ±10% |
| Minor mobile phase components | ±30% relative or ±2% absolute, whichever is larger |
| Column temperature | ±10 °C |
| Injection volume | May be varied provided system suitability criteria are still met |
| Parameter | Permitted adjustment |
|---|---|
| Column length to particle size ratio (L/dp) | Held constant, or within −25% to +50% of the prescribed ratio |
| Flow rate | Adjusted in proportion to the change in column volume |
| Gradient time | Adjusted for the change in column volume |
| Mobile phase pH | ±0.2 pH units |
| Buffer concentration | ±10% |
| Mobile phase composition | Adjustable where system suitability is met and principal peaks elute within ±15% of the prescribed retention time |
| Column temperature | ±5 °C — half the isocratic allowance |
| Injection volume | May be varied provided system suitability criteria are still met |
Gradient methods were historically far more restricted. The harmonised text official from 1 December 2022 aligned the L/dp allowance across both elution modes, so guidance published before that date may understate what is now permitted.[1] Always work from the currently official chapter.
The identity of the bonded substituent cannot be changed. USP 621 does not permit replacement of C18 by C8 — the other physicochemical characteristics of the stationary phase must remain similar.[1] In practical terms, moving from an L1 column to an L7 column is a modification of the procedure, not an adjustment, and triggers validation.
The detector wavelength cannot be adjusted. No change is permitted to the prescribed wavelength.[1]
Where a change falls outside the allowable adjustments, the work becomes a revalidation exercise under ICH Q2(R2) — the guideline reached Step 4 on 1 November 2023 and defines specificity, accuracy, precision, range, detection limit, quantitation limit and robustness as the performance characteristics to demonstrate.[7] Keep the change control, the justification and the raw data traceable; the same ALCOA and ALCOA+ data integrity expectations apply to chromatographic raw data as to any other GMP record.
Common column failures and what actually causes them
Retention loss in highly aqueous mobile phases
Widely described as “phase collapse”, the mechanism is more accurately called phase dewetting. When the organic content falls below about 10%, or reaches zero, the hydrophobic bonded chains self-associate and the mobile phase is expelled from the pores, causing retention shifts and peak distortion. It is reversible by resolvating the phase with a higher organic percentage. Phases with polar embedded groups — amide, urea or carbamate — and those sold with an aqueous-compatible designation resist it.[4] If your method genuinely needs 100% aqueous, specify an L60 polar-embedded amide phase rather than fighting a conventional C18.
Poor peak shape for basic drugs
Residual silanols interacting with protonated bases produce tailing. The corrections are a well-endcapped or polar-embedded phase, adequate buffer strength, and a mobile phase pH set at least two units away from the analyte pKa so the ionisation state is defined rather than drifting. Hybrid-particle phases give more room to move the pH than conventional silica does.[6]
Rising back pressure
Almost always frit blockage rather than damage to the packed bed. Sub-2 µm columns need 0.3–0.5 µm frits, against 2 µm for 3.5–5 µm columns, so they trap particulates that a conventional column would pass. In-line 0.2–0.45 µm filters, guard columns and disciplined sample preparation address the cause.[4]
Assuming a long re-equilibration is always necessary
The customary ten column volumes is more than most separations need. For non-ionisable solutes in unbuffered eluents, repeatable equilibrium — retention time repeatability better than 0.002 minutes — is reached within approximately two column volumes.[4] Establishing the real figure for your method during development, and writing that into the SOP, recovers meaningful run time across a QC shift. Treat this as a validated method parameter, not a shortcut applied at the bench.
Skipping the guard column
In an accelerated lifetime test, an unprotected column failed at injection 85 through accumulation of milk solids, while a guarded system maintained performance past 160 injections with guard cartridge replacements. Modern guard holders add negligible dead volume.[4] Against the price of an analytical column, this is the cheapest control available. Column care, flushing and storage practice belong in a controlled document — see our SOP for preventive maintenance of HPLC for a worked template covering pump, injector, detector and column.
Frequently asked questions
There are eight working types, defined by separation mechanism: reversed phase, normal phase, HILIC, ion-exchange, size-exclusion, chiral, affinity and mixed-mode. Reversed phase accounts for the large majority of pharmaceutical assay and related-substance methods. Separately from mechanism, columns differ in particle architecture: fully porous, superficially porous or core-shell, hybrid organic-inorganic, and monolithic rods.
USP identifies chromatographic packings by an L-designation rather than by brand. L1 is octadecyl silane bonded to porous, non-porous or superficially porous silica or ceramic micro-particles of 1.5 to 10 micrometres, or a monolithic rod. L7 is octylsilane, L11 phenyl, L43 pentafluorophenyl, L14 strong anion exchange and L21 rigid styrene-divinylbenzene copolymer. USP maintains a Chromatographic Columns Database of the columns actually used to validate published procedures, and published listings now run past L120.
No. More than 800 commercial columns carry the L1 designation, built on different base silicas with different bonding reagents and synthetic routes, and four L1 phases run under identical conditions can give visibly different chromatograms. The L-code defines a category of packing, not an equivalence certificate. Use a column characterisation approach such as the hydrophobic subtraction model to shortlist candidates, then prove equivalence with a system suitability run on your own method.
Within limits. USP General Chapter 621 permits the column length to particle size ratio to be held constant or varied from minus 25 percent to plus 50 percent of the prescribed ratio, and permits the internal diameter to be changed, provided system suitability is still met. What is not permitted is changing the identity of the bonded substituent: replacing a C18 packing with a C8 packing is a modification of the procedure, not an adjustment, and requires validation.
If the analyte is polar but neutral, HILIC on bare silica or an amide phase is the usual first choice because it retains what reversed phase cannot hold and stays compatible with mass spectrometry. If the analyte carries a permanent charge, ion-exchange gives stronger and more predictable retention, at the cost of salt in the eluent. Mixed-mode reversed phase plus ion exchange is the option where a sample contains both neutral and charged species that must be resolved in one run.
The analytical column performs the separation and is the one named in the method. A guard column is a short cartridge of the same or compatible packing installed ahead of it, whose only job is to trap particulates and strongly retained matrix components so they never reach the analytical bed. Guard cartridges are consumable and replaced on a defined frequency. In an accelerated lifetime test an unprotected column failed at injection 85, while a guarded system continued past 160 injections.
Method transfer or analytical validation to close out?
We support Indian manufacturers on method transfer, validation protocols, laboratory qualification and audit readiness — drawing on 23 years inside QC, QA and regulatory affairs.
References
- United States Pharmacopeial Convention. 〈621〉 Chromatography. Stage 4 Harmonization, official 1 December 2022. Rockville, MD: USP; 2021. Available from: https://www.usp.org/sites/default/files/usp/document/harmonization/gen-chapter/harmonization-november-2021-m99380.pdf. Accessed August 2026.
- Merck KGaA / Sigma-Aldrich. USP HPLC Columns: packing designations L1–L122. Technical documentation reproducing USP–NF reagent descriptions. Available from: https://www.sigmaaldrich.com/US/en/technical-documents/technical-article/analytical-chemistry/small-molecule-hplc/usp-hplc-columns. Accessed August 2026.
- United States Pharmacopeial Convention. USP Chromatographic Columns Database. Rockville, MD: USP. Available from: https://www.usp.org/resources/chromatographic-columns. Accessed August 2026.
- Majors RE. The Top 10 HPLC and UHPLC Column Myths. LCGC North America. 1 July 2013. Available from: https://www.chromatographyonline.com/view/top-10-hplc-and-uhplc-column-myths-0. Accessed August 2026.
- Fekete S, Guillarme D, Dong MW. Superficially Porous Particles: Perspectives, Practices, and Trends. LCGC North America. 2014;32(6). Available from: https://www.chromatographyonline.com/view/superficially-porous-particles-perspectives-practices-and-trends-0. Accessed August 2026.
- Walter TH. Hybrid Particle Columns: The First Twenty Years. LCGC International. 1 July 2019. Available from: https://www.chromatographyonline.com/view/hybrid-particle-columns-first-twenty-years. Accessed August 2026.
- International Council for Harmonisation. ICH Harmonised Guideline Q2(R2): Validation of Analytical Procedures. Step 4 version, 1 November 2023. Available from: https://database.ich.org/sites/default/files/ICH_Q2%28R2%29_Guideline_2023_1130.pdf. Accessed August 2026.
This article is technical and educational content for pharmaceutical professionals. It is not medical advice, laboratory certification or a regulatory submission. Pharmacopoeial texts and Indian statutory instruments are revised frequently: verify every limit, designation and allowable adjustment against the currently official USP–NF, Indian Pharmacopoeia and ICH text before applying it to a validated method. Where a column change may fall outside allowable adjustments, route it through your site change-control procedure.




